66 HUDSON BOULEVARD EAST, NEW YORK, NY
Pfizer Reaffirms Fiscal Year 2026 Guidance Following CFO Transition
Announces Chief Financial Officer Transition
Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
Shareholder votes
Annual Report to Security Holders
Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
Pfizer Inc. Completes $500 Million Public Offering of Floating Rate Notes
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Certificate
Registration of Securities
SC TO-I
Additional Proxy Materials
Definitive Proxy Statement
Additional Proxy Soliciting Materials
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Specialized Disclosure Report
Automatic Shelf Registration Statement